Hydrocortisone-cypionate - Glucocorticoid Receptor Agonist - 生命科學(xué)試劑 - MedChemExpress_第1頁
Hydrocortisone-cypionate - Glucocorticoid Receptor Agonist - 生命科學(xué)試劑 - MedChemExpress_第2頁
Hydrocortisone-cypionate - Glucocorticoid Receptor Agonist - 生命科學(xué)試劑 - MedChemExpress_第3頁
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)

文檔簡介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEHydrocortisone cypionateCat. No.: HY-U00089CAS No.: 508-99-6分式: CHO分量: 486.64作靶點(diǎn): Glucocorticoid Receptor作通路: GPCR/G Protein儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 125 mg/mL (256.86

2、 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.0549 mL 10.2745 mL 20.5491 mL5 mM 0.4110 mL 2.0549 mL 4.1098 mL10 mM 0.2055 mL 1.0275 mL 2.0549 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請根據(jù)您的實(shí)驗(yàn)動物和給藥式選擇適當(dāng)?shù)娜芙獍?,配制前請先配制澄的儲備液,再依次添加助溶?為保證實(shí)驗(yàn)結(jié)果的可靠性,體內(nèi)實(shí)驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄的儲備

3、液可以根據(jù)儲存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (4.27 mM); Clear solution2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (4.27 mM); Clear solution3. 請依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.08 mg/mL

4、 (4.27 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 Hydrocortisone cypionate種合成的糖質(zhì)激素和質(zhì)類醇酯。體外研究 Hydrocortisone (50 nM) shows a dose-dependent down-regulation of GR transcript in hCMEC/D3 cells.Hydrocortisone supplementation of the serum-reduced cell diffe

5、rentiation medium leads to a significantincrease in TER across the hCMEC/D3 monolayer 1. Hydrocortisone-treated Dendritic cells (DCs) show adecreased expression of MHC II molecules, the costimulatory molecule CD86, and the DC-specific markerCD83, as well as a strongly reduced IL-12 secretion. Hydroc

6、ortisone-treated DCs inhibit production of IFN-but induce an increased release of IL-4 and no change in IL-5 2. Hydrocortisone reduces postischemicoxidative stress, perfusion pressure, and transudate formation. Hydrocortisone inhibits postischemicshedding of syndecan-1, heparan sulfate, and hyaluron

7、an as is release of histamine from resident mast cells3.REFERENCES1. F?rster C, et al. Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol. 2008 Apr 1;586(7):1937-49.2. Bellinghausen I, et al. Inhibition of h

8、uman allergic T-cell responses by IL-10-treated dendritic cells: differences from hydrocortisone-treated dendritic cells. J Allergy Clin Immunol. 2001 Aug;108(2):242-9.3. Chappell D, et al. Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. Anesthesiology. 2007Nov;107(5):776-84.McePdfHeightCaution: Product has not been fully validated for medical application

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論